
|Videos|August 18, 2022
Dr. Jang on current state of immunotherapy in advanced GU cancers
Author(s)Urology Times staff
There are still quite a few patients who still do not respond to immunotherapy, says Albert Jang, MD.
Advertisement
Albert Jang, MD, a 3rd-year internal resident physician at Tulane University, discusses progress and unmet needs with immunotherapy for the treatment of patients with genitourinary cancers.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC
2
Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC
3
Choosing salvage therapy after prostate cancer focal ablation
4
SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort
5


















